Association between medical comorbidities at diagnosis and paediatric acute lymphoblastic leukaemia and lymphoblastic
Ernest K Amankwah1, Maua Mosha2, Jennifer Dean3
1The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ernest@jhu.edu.
Insights
This systematic review examines how medical comorbidities at diagnosis impact treatment outcomes for pediatric acute lymphoblastic leukemia and lymphoma. Findings will inform clinical practice and future research for better patient care.
Area of Science:
- Pediatric Oncology
- Hematology
- Systematic Review Methodology
Background:
- Medical comorbidity significantly influences cancer treatment outcomes.
- Understanding these associations is crucial for optimizing care in pediatric cancers.
- Paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma are common childhood cancers.
Purpose of the Study:
- To systematically synthesize existing evidence on the relationship between medical comorbidities and outcomes in pediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma.
- To identify specific comorbidities that affect treatment success and survival rates.
Main Methods:
- A comprehensive systematic literature review of MEDLINE and EMBASE databases.
- Inclusion of studies in English from database inception to September 2022, focusing on human subjects.
- Independent screening, data extraction, and risk of bias assessment by two reviewers, with potential for meta-analysis.
Main Results:
- Data extraction will focus on treatment-related outcomes and survival.
- A narrative and tabular summary will be provided, or a meta-analysis if data permit.
- Results will highlight the impact of comorbidities on treatment efficacy and prognosis.
Conclusions:
- The study will provide a synthesized overview of current evidence on comorbidities in pediatric leukemia and lymphoma.
- Findings are expected to guide clinical decision-making and improve patient management strategies.
- Dissemination through peer-reviewed publications will share critical insights with the medical community.
Introduction:
Medical comorbidity at diagnosis is associated with treatment outcome in cancer. The aim of this project is to synthesise the evidence on the association between medical comorbidities and paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma outcomes.
Methods And Analysis:
A systematic review of the literature will be conducted by developing a search strategy that will combine medical subject headings and natural language key words related to acute lymphoblastic leukaemia or lymphoma, medical comorbidities and treatment-related outcomes. We will search MEDLINE and EMBASE to identify studies in human subjects and written in English from the inception of each database to 30 September 2022. Two authors will independently screen the titles and abstracts of retrieved studies based on the inclusion and exclusion criteria to identify potentially eligible studies. Full-text articles of eligible studies and final included articles will be retrieved and reviewed in a similar manner by two independent reviewers. Data extraction from included articles will be conducted independently by two authors using a standardised data extraction form. Risk of bias in the included studies will be assessed using existing relevant tools. A narrative and tabular summary of the data, including outcomes, will be provided if the data do not warrant a meta-analysis. If a meta-analysis is feasible, we will pool all the effect estimates. Heterogeneity among study effect sizes will be tested with Cochran's Q test and quantified by the I2 statistic.
Ethics And Dissemination:
This study will not include the collection of original data, but it will be a summary of aggregate existing data. Thus, ethics approval is not applicable. The findings of the study will be disseminated through peer-reviewed publications.
Prospero Registration Number:
CRD42022366669.
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:21Cancer Survival Analysis
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:20Comparing the Survival Analysis of Two or More Groups